https://doi.org/10.55788/18b0feb1
The investigation, presented by Dr Jose Maria Remes-Troche (Veracruzana University, Mexico), was a double-blind, placebo-controlled clinical trial (NCT03803319) conducted across Mexico and the United Kingdom [1]. It evaluated the effect of co-administering distinct types of dietary fibres on IBS patients. Participants were given either a placebo, a combined dose of extracted fibres (inulin and psyllium), or native fibres (nopal) twice daily over 8 weeks. The trial's main objective was to measure the impact of these interventions on the patients' gut microbiota and IBS symptoms. Secondary objectives included evaluating stool consistency, gut transit times, and microbial metabolites.
A total of 133 patients were included who were randomised to inulin/psyllium (n=47), nopal (n=44), or placebo (n=42). The results revealed no significant differences in the relief of IBS symptoms assessed by the Global Symptom Question across the 3 groups (P=0.724). However, the incidence and severity of constipation and hard stools were notably reduced in the inulin/psyllium (4.5%) compared with nopal (15.1%, P=0.026) and placebo (15.6%, P=0.02).
Additionally, the inulin/psyllium group exhibited a decreased Shannon diversity index (4.0) in contrast to both nopal (4.4, P=0.024) and placebo (4.5, P=0.016). In particular, inulin/psyllium resulted in a lower abundance of Ruminococcus (P=0.001), Dorea (P=0.016), and Coprococcus (P=0.011) and higher Bifidobacteria (P=0.055). These changes were not associated with short-chain fatty acid production alterations, suggesting a unique effect on the gut microbiome's composition.
Overall, the co-administration of inulin and psyllium was shown to mitigate constipation without exacerbating IBS symptoms, despite not leading to overall clinical improvements. These findings suggest the potential for personalised, fibre-based interventions in IBS management based on individual symptom profiles and microbiota configurations.
- Remes-Troche JM, et al. Fiber co-administration and impact on symptoms, gut transit time and gut microbiome in irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Lecture 1248, DDW 2023, 6–9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Daily and seasonal fluctuations in the gut microbiome Next Article
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection »
« Daily and seasonal fluctuations in the gut microbiome Next Article
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection »
Table of Contents: DDW 2023
Featured articles
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Upper GI Disorders: Hot Topics
Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation
Inflammatory Bowel Disease: Novel Developments
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Microbiota in GI Diseases
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection
IBS management: the complex role of dietary fibres
Daily and seasonal fluctuations in the gut microbiome
Spotlight on Colorectal Cancer
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
What is New in Hepatology?
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy